- Neurocrine Biosciences (NASDAQ:NBIX) announced that its investigational calcium channel blocker NBI-827104 did not meet the main goal in a Phase 2 trial in patients with the pediatric disorder, epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS).
- The placebo-controlled STEAMBOAT trial was designed to evaluate the once-daily administration of NBI-827104 for up to 13 weeks in pediatric patients with EE-CSWS, a disorder characterized by abnormal sleeping patterns.
- When measured after six weeks of therapy, the trial did not meet the primary endpoint of decline in the ratio of the spike-wave index (SWI) from baseline as compared to the placebo, the company said, adding that the study drug was, however, well tolerated.
- "While we did not meet the primary endpoint for this Phase 2 study, we remain committed to advancing care for patients living with epilepsy, including rare pediatric forms," Chief Medical Officer of Neurocrine (NBIX) Eiry W. Roberts remarked.
- "We will continue to analyze the rich data set generated from this study to determine next steps."
- Read: Despite multiple catalysts ahead, Wells Fargo launched its coverage on Neurocrine (NBIX) in September with an Equal Weight rating.
Neurocrine says candidate for childhood epileptic disorder did not meet main goal
Recommended For You
More Trending News
About NBIX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
NBIX | - | - |
Neurocrine Biosciences, Inc. |